NRG1 and neoplasm: A 47-year-old woman with metastatic pancreatic cancer, who had progressed on multiple prior therapies including, but not limited to folinic acid, fluorouracil, irinotecan, and oxaliplatin, gemcitabine plus nab-paclitaxel, and a pembrolizumab-based treatment, had next-generation sequencing, which showed microsatellite-stable (MSS), tumor mutation burden (TMB) of 7 mutations/megabase, CREBBP exon 16 p.E1058fs, PBRM1 exon 12 p.Y417fs, and a VTCN1-NRG1 fusion (Caris Life Sciences and Ashion/Exact Sciences).